Monopar Therapeutics MNPR Total debt

Total debt at other companies

Bristol-Myers SquibbBMY

$43.33B-12.3%

Eli LillyLLY

$54.91B+37.6%

Bausch Health CompaniesBHC

$20.76B-3.5%

Wave Life SciencesWVE

$43.59M+101%

Prime MedicinePRME

$112.48M-6.1%

Perspective TherapeuticsCATX

$3.91M+11.1%

FAQ

What is Monopar Therapeutics's total debt?

Monopar Therapeutics (MNPR) reported total debt of $230.43K in Q1 2026.

How has Monopar Therapeutics's total debt changed year-over-year?

Monopar Therapeutics's total debt increased by 2692.4% year-over-year, from $8.25K to $230.43K.

What is the long-term trend for Monopar Therapeutics's total debt?

Over 2 years (2022 to 2025), Monopar Therapeutics's total debt has grown at a 107.5% compound annual growth rate (CAGR), from $56.99K to $245.49K.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.